temozolomide has been researched along with Pneumocystis Infections in 2 studies
Pneumocystis Infections: Infections with species in the genus PNEUMOCYSTIS, a fungus causing interstitial plasma cell pneumonia (PNEUMONIA, PNEUMOCYSTIS) and other infections in humans and other MAMMALS. Immunocompromised patients, especially those with AIDS, are particularly susceptible to these infections. Extrapulmonary sites are rare but seen occasionally.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment." | 9.11 | Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. ( Cohen, MH; Johnson, JR; Pazdur, R, 2005) |
| "Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM)." | 9.10 | Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. ( de Tribolet, N; Dietrich, PY; Janzer, R; Leyvraz, S; Maeder, P; Maillard, I; Meuli, R; Miralbell, R; Mirimanoff, RO; Ostermann Kraljevic, S; Pica, A; Pizzolato, G; Porchet, F; Regli, L; Stupp, R, 2002) |
| " Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment." | 5.11 | Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. ( Cohen, MH; Johnson, JR; Pazdur, R, 2005) |
| "Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM)." | 5.10 | Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. ( de Tribolet, N; Dietrich, PY; Janzer, R; Leyvraz, S; Maeder, P; Maillard, I; Meuli, R; Miralbell, R; Mirimanoff, RO; Ostermann Kraljevic, S; Pica, A; Pizzolato, G; Porchet, F; Regli, L; Stupp, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MH | 1 |
| Johnson, JR | 1 |
| Pazdur, R | 1 |
| Stupp, R | 1 |
| Dietrich, PY | 1 |
| Ostermann Kraljevic, S | 1 |
| Pica, A | 1 |
| Maillard, I | 1 |
| Maeder, P | 1 |
| Meuli, R | 1 |
| Janzer, R | 1 |
| Pizzolato, G | 1 |
| Miralbell, R | 1 |
| Porchet, F | 1 |
| Regli, L | 1 |
| de Tribolet, N | 1 |
| Mirimanoff, RO | 1 |
| Leyvraz, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study[NCT00006353] | Phase 3 | 575 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for temozolomide and Pneumocystis Infections
| Article | Year |
|---|---|
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2005 |
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2002 |